Nilo Therapeutics launched out of academic labs with a $101 million Series A to translate neuro‑immunology discoveries into therapies for autoimmune and inflammatory diseases. The New York‑based company, founded by leaders from Columbia, Yale and Harvard, will pursue programs that target vagal and other brain‑to‑immune circuits identified in foundational neuroscience research. The round was led by The Column Group, DCVC Bio and Lux Capital with Gates Foundation participation. Nilo plans to use the proceeds to build labs, hire R&D staff and advance preclinical programs; its approach seeks to modulate 'master regulator' neural circuits rather than single peripheral immune targets. Clarification: neuro‑immunology here refers to the study and therapeutic targeting of brain‑to‑body pathways that regulate systemic immunity.